Can taking Fruquintinib shrink tumors?

Fruquintinib (Fruquintinib) is a polytyrosine kinase inhibitor that blocks the formation and growth of tumor blood vessels mainly by inhibiting vascular endothelial growth factor receptor (VEGFR). Clinical studies have shown that fruquintinib has achieved significant clinical effects in the treatment of cancers such as advanced colorectal cancer and gastric cancer, and for some patients, tumor shrinkage can indeed be observed.

The mechanism of fruquintinib mainly inhibits the growth and spread of tumors by targeting the angiogenesis process, inhibiting the formation of tumor blood vessels and reducing blood supply. This effect makes fruquintinib an effective anti-angiogenic drug, providing a new treatment option for some patients who are inoperable or have already received other treatments.

However, factors such as individual differences and disease variability may cause patients to respond differently to fruquintinib. Some patients may show better tolerance and efficacy of the drug, while others may show poorer results. Therefore, when using fruquintinib for treatment, doctors usually develop an individualized treatment plan based on the patient's specific conditions, monitor the efficacy and adjust the dose to maximize the therapeutic effect.

In general, fruquintinib, as a targeted therapy, has the potential to shrink tumors for some patients with advanced cancer, but the therapeutic effect is still affected by a variety of factors and needs to be used rationally under the guidance of a doctor.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.